• Northwest Biotherapeutics entered a collaboration with UK NHS Blood and Transplant to support production of its experimental cancer vaccine DCVax-L.
• NHSBT will provide therapeutic apheresis and cell processing to supply immune-cell starting material for personalized manufacturing.
• Initial UK work will run through Leeds and Oxford, with a phased expansion to additional NHSBT sites across England under evaluation.
• Advent Bioservices will work alongside NHSBT to strengthen UK manufacturing infrastructure for DCVax-L.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Northwest Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF67494) on October 08, 2026, and is solely responsible for the information contained therein.